# US 2023/0390252 A1 · Use of riluzole prodrugs to treat ataxias

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390252 A1
- Document ID: US20230390252A1
- Status: Published application
- Kind: A1
- Application number: 18/353,840
- Filed: 2023-07-17
- Published: 2023-12-07
- Earliest claimed: 2017-11-12
- Assignees: Biohaven Therapeutics Ltd.
- Applicants: Biohaven Therapeutics Ltd.
- Inventors: Vladimir CORIC; Robert BERMAN; Melissa BEINER; Gilbert L'Italien
- Web page: https://patentgrep.com/patent/US20230390252A1

## CPC

- A61K 31/428: condensed with carbocyclic rings
- A61K 9/2063: {Proteins, e.g. gelatin}
- A61K 9/485: {Inorganic compounds}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 35/00: Antineoplastic agents
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- C07D 277/82: Nitrogen atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed are methods of treating ataxia by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method of treating spinocerebellar ataxia type 3 in a patient, comprising administering to the patient in need of such treatment a therapeutically effective amount of a riluzole prodrug having the following formula:
or pharmaceutically acceptable salts thereof, wherein:
R23 is selected from the group consisting H, CH3, CH2CH3, CH2CH2CH3, CH2CCH, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2OH, CH2OCH2Ph, CH2CH2OCH2Ph, CH(OH)CH3, CH2Ph, CH2(cyclohexyl), CH2(4-OH-Ph), (CH2)4NH2, (CH2)3NHC(NH2)NH, CH2(3-indole), CH2(5-imidazole), CH2CO2H, CH2CH2CO2H, CH2CONH2, and CH2CH2CONH2.

### Claim 20 (depends on 19)

The method of claim 19, wherein the riluzole prodrug has the following formula:

### Claim 21 (depends on 19)

The method of claim 19, wherein the treatment provides an improvement in the patient's total SARA score of at least 0.8, or 0.9, or 1.0, or 1.1, or 1.2, or 1.3, or 1.4, or 1.5, or 1.6, or 1.7, or 1.8, or 1.9, or 2.0, or greater.

### Claim 22 (depends on 19)

The method of claim 19, wherein the riluzole prodrug is administered to the patient at a dosage of from about 17.5 to 200 mg per day.

### Claim 23 (depends on 22)

The method of claim 22, wherein the riluzole prodrug is administered to the patient at a dosage of about 17.5, or 35, or 70, or 100, or 140, or 200 mg per day.

### Claim 24 (depends on 23)

The method of claim 23, wherein the riluzole prodrug is administered to the patient at a dosage of 200 mg, once per day.

### Claim 25 (depends on 23)

The method of claim 23, wherein the riluzole prodrug is administered to the patient at a dosage of 140 mg, once per day.

### Claim 26 (depends on 19)

The method of claim 19, wherein the riluzole prodrug is administered to the patient once per day.

### Claim 27 (depends on 19)

The method of claim 19, wherein the riluzole prodrug is administered to the patient twice per day.

### Claim 28 (depends on 19)

The method of claim 19, wherein the riluzole prodrug is administered to the patient in the form of a capsule.

### Claim 29 (depends on 19)

The method of claim 19, wherein the riluzole prodrug is administered to the patient in the form of a tablet.

### Claim 30 (depends on 19)

The method of claim 19, wherein the riluzole prodrug is administered to the patient for a duration of from about 8 weeks to 48 weeks.

### Claim 31 (depends on 19)

A kit for treating a patient afflicted with spinocerebellar ataxia type 3, the kit comprising:
(a) a riluzole prodrug having the following formula:
or pharmaceutically acceptable salts thereof, wherein:
R23 is selected from the group consisting H, CH3, CH2CH3, CH2CH2CH3, CH2CCH, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2OH, CH2OCH2Ph, CH2CH2OCH2Ph, CH(OH)CH3, CH2Ph, CH2(cyclohexyl), CH2(4-OH-Ph), (CH2)4NH2, (CH2)3NHC(NH2)NH, CH2(3-indole), CH2(5-imidazole), CH2CO2H, CH2CH2CO2H, CH2CONH2, and CH2CH2CONH2; and
(b) instructions for administering the riluzole prodrug in the method of claim 19.

### Claim 32 (depends on 31)

The kit of claim 31, wherein the riluzole prodrug has the following formula:
